When should I initiate evolocumab (Repatha) in a statin‑intolerant patient after other oral lipid‑lowering therapies have been exhausted?

When to Start Repatha (Evolocumab) in Statin-Intolerant Patients

In statin-intolerant patients with established atherosclerotic cardiovascular disease (ASCVD) or acute coronary syndrome (ACS), initiate evolocumab (Repatha) immediately after confirming true statin intolerance—defined as inability to tolerate at least 2 different statins including one at the lowest approved daily dose—without waiting to exhaust other oral therapies. 1

Confirming True Statin Intolerance

Before initiating evolocumab, you must objectively confirm statin intolerance:

• Attempt at least 2 different statins, including at least 1 at the lowest approved daily dose 1
• True complete statin intolerance applies to <3% of patients 1
• Most common cause is statin-associated muscle symptoms 1
• Use objective criteria (such as the MEDS algorithm) to distinguish genuine intolerance from non-adherence 1

Immediate Initiation Strategy by Clinical Context

For ACS/Post-MI Patients (Highest Priority)

Start evolocumab immediately upon hospital discharge or during hospitalization if the patient meets statin intolerance criteria. 1

According to the 2025 ACC/AHA guidelines for ACS management:

• If LDL-C ≥70 mg/dL and statin intolerant: Add nonstatin therapy (Class 1 recommendation) 1
• If LDL-C 55-69 mg/dL and statin intolerant: LDL-lowering therapy is reasonable (Class 2a recommendation) 1
• If LDL-C <55 mg/dL and statin intolerant: Continue monitoring 1

The guideline explicitly states that nonstatin options include ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), and/or bempedoic acid. 1

For Extremely High-Risk Patients

Initiate evolocumab immediately without delay if the patient has complete statin intolerance and meets any of these criteria:

• MI + previous vascular event in last 2 years 1
• ACS + multivessel disease 1
• ACS + peripheral arterial disease 1
• ACS + familial hypercholesterolemia 1
• ACS + diabetes + additional risk factor (hsCRP >2 mg/L, chronic kidney disease, or Lp(a) >50 mg/dL) 1

Target LDL-C <40 mg/dL in these patients. 1

Sequencing Strategy: When to Choose Evolocumab vs. Other Options

Complete Statin Intolerance (Cannot Tolerate Any Statin)

First-line approach: Consider bempedoic acid/ezetimibe combination initially if available, as this provides oral therapy with proven cardiovascular outcomes. 1, 2

Add or switch to evolocumab when:

• LDL-C remains ≥55 mg/dL (or ≥40 mg/dL in extremely high-risk patients) after 4-6 weeks on bempedoic acid/ezetimibe 1
• Baseline LDL-C is very high (>190 mg/dL), making oral therapy alone insufficient 1
• Patient has familial hypercholesterolemia requiring more aggressive LDL-C reduction 3, 4

Partial Statin Intolerance (Can Tolerate Low-Dose Statin)

Preferred strategy: Combine maximally tolerated statin dose with ezetimibe first. 1

Add evolocumab when:

• LDL-C target not achieved after 4-6 weeks on statin + ezetimibe 1
• Consider adding bempedoic acid before evolocumab if available and patient prefers oral therapy 1, 2
• For extremely high-risk patients, consider triple therapy (statin + ezetimibe + evolocumab) upfront 1

Dosing and Administration

Standard dosing: 140 mg subcutaneously every 2 weeks OR 420 mg once monthly 4, 5, 6

• Both regimens provide equivalent LDL-C reduction of 50-65% 3, 4, 5
• Monthly dosing may improve adherence in some patients 1
• Administered subcutaneously in thigh, abdomen, or upper arm 4

Expected Outcomes and Monitoring

Efficacy:

• LDL-C reduction of 53-56% in statin-intolerant patients 7
• Mean LDL-C levels of approximately 35 mg/dL achievable 3
• Also reduces lipoprotein(a) by up to 25% 3
• 15% relative risk reduction in major adverse cardiovascular events over 2-3 years 1

Monitoring schedule:

• Check lipid panel 4-6 weeks after initiation 1
• If LDL-C target achieved, follow-up at 3 months 1
• If target not achieved, intensify therapy further or refer to lipid center 1

Safety Profile

Evolocumab is well-tolerated with favorable safety compared to ezetimibe in statin-intolerant patients:

• Muscle adverse events occurred in only 12% of evolocumab-treated patients vs. 23% with ezetimibe 7
• Common side effects: nasopharyngitis, upper respiratory infection, back pain, injection site reactions 4
• No neurocognitive effects or antidrug antibody production in >60,000 patient-years 8
• Safe to achieve very low LDL-C levels without safety concerns 1

Critical Pitfalls to Avoid

Do not delay PCSK9 inhibitor initiation by slowly titrating oral therapies in high-risk statin-intolerant patients, as this increases LDL-C visit-to-visit variability and recurrent cardiovascular events. 1

Do not de-escalate therapy once low LDL-C levels are achieved if the patient tolerates treatment well. 1

Do not assume statin intolerance without attempting at least 2 different statins at appropriate doses—many patients labeled as "intolerant" can actually tolerate lower doses or different statins. 1

Consider patient preference regarding injection frequency (every 2 weeks vs. monthly) and willingness to self-inject, as adherence is critical for long-term benefit. 8